# Quest Diagnostics (DGX) Stock Analysis: A Look at Its 10% Upside Potential and Solid Dividend Yield

- Link: https://www.directorstalkinterviews.com/quest-diagnostics-dgx-stock-analysis-a-look-at-its-10-upside-potential-and-solid-dividend-yield/4121208392
- Published: 2025-07-21T10:19:50+01:00
- Author: Madison Wilson

For individual investors searching for a steady player in the healthcare sector,
Quest Diagnostics Incorporated (NYSE: DGX) presents a compelling case. With a market
capitalization of $18.63 billion, Quest Diagnostics stands as a formidable entity
in the Diagnostics & Research industry, offering a range of diagnostic information
services. Founded in 1967 and headquartered in Secaucus, New Jersey, the company
has built a diversified portfolio under various brands, including Quest Diagnostics,
AmeriPath, Dermpath Diagnostics, and ExamOne.

Quest Diagnostics’ current stock price sits at $166.91, marginally down by 0.01%
from its previous close. However, the average target price set by analysts is $183.92,
suggesting a potential upside of approximately 10.19%. This could be an attractive
proposition for investors seeking growth opportunities in the healthcare sector.

The company has demonstrated robust revenue growth at 12.10%, a testament to its
strong operational performance and market demand for its diagnostic services. Despite
the absence of available net income data, the reported earnings per share (EPS) 
of 7.91 and a return on equity (ROE) of 13.95% reflect the company’s ability to 
generate profits and deliver value to its shareholders.

Valuation metrics indicate a forward P/E ratio of 15.86, which could be considered
reasonable within the healthcare industry, especially given the company’s solid 
financials and market position. The absence of a trailing P/E, PEG ratio, and other
valuation figures suggests a need for investors to delve deeper into the company’s
financial statements to fully understand its valuation dynamics.

Quest Diagnostics also offers a dividend yield of 1.78%, with a payout ratio of 
48.04%. This suggests a balanced approach to rewarding shareholders while retaining
sufficient capital for reinvestment. For income-focused investors, this dividend
yield, coupled with the company’s growth prospects, could enhance the attractiveness
of including DGX in their portfolio.

Analyst ratings for Quest Diagnostics are mixed, with 9 buy ratings, 9 hold ratings,
and 1 sell rating. This reflects a cautious optimism about the company’s future 
prospects. The 52-week price range of $140.96 to $182.07 indicates the stock’s relative
stability, with the current price hovering closer to the upper end of the range.

From a technical perspective, the stock’s 50-day moving average stands at $174.93,
while the 200-day moving average is at $164.82, suggesting a minor downward trend
in the short term. The Relative Strength Index (RSI) of 52.85 indicates that the
stock is neither overbought nor oversold, presenting a neutral outlook for technical
traders.

In summary, Quest Diagnostics offers a blend of growth potential and dividend income,
making it a viable option for investors looking to diversify their holdings in the
healthcare sector. The company’s robust revenue growth, solid EPS, and promising
upside potential underscore its capability to deliver shareholder value. However,
investors should remain vigilant of market conditions and conduct their due diligence,
considering both the analyst ratings and technical indicators before making investment
decisions.

Share on: